

Development and validation of a tool to improve community pharmacists' surveillance role in the safe dispensing of herbal supplements

Ammar A. Jairoun^{1,2*}, Sabaa S. Al Hemyari¹, Naseem M. Abdulla², Moyad Shahwan³, Maimona Jairoun⁴, Brian Godman⁵, Faris El-Dahiyat⁶, Amanj Kurdi⁵

¹Universiti Sains Malaysia (USM), Malaysia

²Dubai Municipality, United Arab Emirates

³Clinical Pharmacy Department, College of Pharmacy, Ajman University of Science and Technology, United Arab Emirates

⁴College of Pharmacy, Ajman University of Science and Technology, United Arab Emirates

⁵ Strathclyde Institute of Pharmacy and Biomedical Sciences, Faculty of Science, University of Strathclyde, Glasgow, UK

⁶Al Ain University, United Arab Emirates

(Accepted for publication *Frontiers in Pharmacology Specialty Section: Ethnopharmacology*)

Abstract

Background: There has been an appreciable increase in the use of herbal supplements, including immune boosters, during the current COVID-19 pandemic. However, there are concerns with falsified herbal supplements.

Objectives Developed a new questionnaire that can potentially help community pharmacists identify the extent of falsified herbal supplements.

Methods: A 9-month cross sectional study was conducted among 500 community pharmacies across United Arab Emirates. A new 5-factor, 24-items scale was developed based on current labelling requirements across countries and piloted. This included 7 items on identified uses and contraindication, 7 items on hazard identification, 4 items on product identity, 3 items on packaging and product insert and 3 items on product handling and

storage. The face and content validity of the scale was assessed via the content validity index (CVI). Its construct validity was tested using an exploratory factor analysis (EFA) via principally component analysis (PCA). The model was subsequently confirmed through Partial confirmatory factor analysis (PCFA). Reliability was assessed via test-retest reliability, internal consistency, item internal consistency (IIC), and intraclass correlation coefficients (ICCs).

Results: The CVI of the finalized 0.843. The Kaiser-Meyer-Olkin measure of sampling adequacy was 0.891, and Bartlett's test of sphericity indicated significance (p -value < 0.001). Confirmation of the subsequent 5-domains was achieved through PCFA using maximum likelihood analysis with oblimin rotation. The PCFA obtained values of 0.962 for NFI, 0.977 for CFI, and 0.987 for the Tucker Lewis Index. All values were greater than 0.95, and the RMSEA value was 0.03 (i.e., less than 0.06). Consequently, the model had a good fit. All domains demonstrated Cronbach's alpha coefficients above 0.70, with 0.940 for the full instrument. Meanwhile, all items met the IIC correlation standard of ≥ 0.40 . The instrument presented good ICC statistics of 0.940 (0.928 – 0.950) as well as statistical significance ($p < 0.001$). Community pharmacists with more than 10 experience years were more likely to identify falsified herbal supplements compared to those with 1 to 10 years experience ($p < 0.001$). **Conclusions:** This study developed and validated a new instrument to identify safe herbal supplements, which should enhance the role of the community pharmacists in the safe and effective treatment of suitable patients with herbal supplements.

1. Introduction

There is a rise in the use of herbal medicines across countries, which can also be referred to with terms including alternative medicines, botanical products, complimentary medicines, natural products and traditional medicines, with an appreciable proportion of the world's population now using herbal medicines to treat some of their diseases (1-5). Overall, it is expected that the herbal medicine market will grow at an annual compounded growth rate of over 7.2% between 2021 and 2026 due to their lower costs, accessibility, and belief that herbal medicines can promote healthier life-styles, treat diseases such as the metabolic syndrome and gastrointestinal problems, and typically have less side-effects than prescribed medicines, which can be a concern with the toxicity of some prescribed medicines (1, 3, 4, 6-10). This is despite concerns with the evidence base of some herbal medicines (5, 9, 11), as well as potentially increased liver and kidney toxicity exacerbated by some herbal medicines containing heavy metals and naturally occurring organic toxins (2, 10, 12, 13). However, there are relatively infrequent reports of adverse reactions with herbal medicines across countries (14). In addition, the quality of some herbal medicines can also vary substantially impacting on their potential toxicity as seen recently with Danshen (13). These concerns though have not impacted on the growth of this market.

However of concern are the differences in the legislation surrounding the regulations and sale of herbal medicines across countries (6, 15). In the USA, for instance, the Food and Drug Administration (FDA) requires that herbal supplements labels should include

information pertaining to its name, name and address of the manufacturer, and a complete list of the ingredients including the amount of each active substance (16). This though is not universal, and it is increasingly likely that these issues will need to be addressed to enhance the safe use of herbal medicines as their evidence base grows. This may well require changes in culture as well as harmonized standards on key issues such as quality control as well as evidence standards across countries as their use grows (5, 17). The same issues are seen with the use of dietary supplements where again there can be both benefits and concerns (18-20).

Another key concern is that the increased use of herbal medicines has been accompanied by their adulteration, which includes increased use of synthetic compounds to increase profit levels; however, this leads to concerns with quality control unless proactively addressed (7, 13). Alongside this, there have also been an increase in the extent of falsified medicines, including herbal medicines, for both life style and health-related conditions across countries (7, 8, 21, 22). Examples of include adulteration or contamination of herbal weight-loss products as well as herbal preparations for inflammatory diseases, blood pressure control and the treatment of certain central nervous system disorders including depression (7, 23-29).

Community pharmacists play a key role in patient care across countries, enhanced by the fact that they are often being the first point of healthcare professional contact for patients for most non-severe conditions, which includes patients with suspected COVID-19 where hospitalization is not required (30-32). Encouragingly, they also typically appear to have good knowledge regarding the indications, side-effects and contraindications of herbal medicines (3, 33, 34). However, this is not always the case as seen in a recent study

conducted in Palestine (35) and in the US where practicing pharmacists identified a number of barriers to enable safe and appropriate dispensing of nutritional and herbal supplements (36). Identified barriers included a lack of education and training surrounding nutritional and herbal supplements as well as concerns regarding regulatory standards and the efficacy and safety of these supplements (36) Harnett et al (2019) also identified key concerns among pharmacists to enhance the use of herbal medicines. This included their education and training to ensure high standards regarding the safety and quality assurance of supplements (37). However, until recently no formal framework appears to be in operation to describe the responsibilities of community pharmacists in dispensing herbal medicines, although this is now changing (11, 38, 39).

In view of these concerns, there is a need to develop a new approach that can help community pharmacists identify the quality of the herbal supplements they dispense. This includes identifying falsified herbal supplements based on the regulatory label requirements of the European Union, the United States FDA and the Dubai Municipality Health and Safety Department, United Arab Emirates (UAE) (40-43). This builds on initiatives across countries, including African countries, to reduce the extent of falsified medicines (44, 45) as well as initiatives such as DNA barcodes or amplicon metabarcoding (AMB) to detect contaminated products alongside routine surveillance activities (27-29, 46).

Consequently, to address this need whilst techniques such as AMB develop, we compiled and evaluated different label requirements of dietary herbal supplement products across different Health Regulatory Authorities, including US, EU and the UAE. The objective is to develop and validate a potential novel self-reporting tool to improve the routine identification of falsified dietary herbal supplements among community pharmacist in the UAE and wider. Such tools can potentially be useful, along with addressing pertinent

education and training requirements, , to promote the safe and appropriate dispensing of herbal supplements in community pharmacies (36, 37). .The findings can subsequently be used across countries to tackle this increasingly important issue.

2. Method

2.1 Study design and setting

This study was a descriptive analytical cross-sectional study conducted over nine months from January 2021 to September 2021 among community pharmacies across the UAE, which included Abu Dubai, Dubai and the Northern Emirates.

This included a pilot study to test the questionnaire before full roll out. Subsequently, evaluate the face and content validity of the questionnaire using standard approaches for use in the future. We adopted a similar methodology to our recently published paper regarding falsified hand sanitisers at the start of the pandemic (47).

English was chosen as the language for the questionnaire as it is the international scientific language and the common language for scientific research scientists globally. In addition, potentially enhancing the usefulness of any tool subsequently developed.

Figure 1 describes the development and validation process.

2.2 Study participants (inclusion and exclusion criteria)

The study subjects were chosen based on pre-specified inclusion and exclusion criteria. The inclusion criteria were community pharmacists who had three months' professional experience or more and were registered with one of the three regulatory bodies, i.e. the Ministry of Health, the Health Authority Abu Dhabi (HAAD), or Dubai Health Authority.

2.3 Pilot testing

A pilot study was undertaken to test the face validity of the developed tool among 22 community pharmacists, whose data were subsequently excluded from the final analysis. The pilot study was undertaken between January 12, 2021 and January 22, 2021. The outcomes of the pilot study were employed to calculate the sample size needed for the main research and to check its reliability.

The questionnaire was sent to 25 purposively selected community pharmacists from which there were 22 respondents, yielding a response rate of 88%.

2.4 Research instrument development and conceptualization

2.4.1 Face and content validity

The questionnaire was developed based on current labelling requirements of the European Union and the United States FDA, and the Dubai Municipality Health and Safety department (**Figure 1**). In their labeling requirements, key information including the Brand name, the name of the manufacturer, the country of origin, the ingredients, product names, pack sizes, Production & Expiration Dates, Storage Conditions, Dosage and Instruction of Use, Product indications / intended use, any Health warnings, Identification Code: (Barcode) and Batch Number are all required to be printed on dietary herbal supplement product labels. The labelled indications are designed to provide users with a clear identification of the functioning and proper use of any dietary herbal remedy, as well as to safeguard the user from commercial considerations and, most importantly, from safety concerns. Labelling should also provide the information required for easy tracing of product data and all toxicologically relevant data. Under normal presentation conditions, the lettering used for dietary herbal supplement product labelling must be permanent, easy to read, and be readily apparent, e.g., in terms of contrast with the background and size.

The initial draft of the questionnaire was subjected to face and content validity by a panel of experts, which comprised two community pharmacists, two regulatory pharmacists, three academics and two industrial pharmacists.

The content validity index (CVI) and ratio (CVR) were calculated by asking every expert to mark each item in the questionnaire as essential or non-essential. A CVR of 0.78 or higher could be considered as evidence of good content validity. If an item does not reach this threshold, it would normally be deleted from the final instrument. Following this, the CVI was obtained by calculating the mean of the CVR values for all items meeting CVR threshold of 0.78 and retained for the final instrument (48, 49).

2.4.2 Construct validity

Construct validity was tested using an exploratory factor analysis (EFA). The factor analysis was conducted by a principal component analysis (PCA), followed by Varimax rotation with Kaiser-Meyer-Olkin (KMO) and Bartlett's test of sphericity to determine the number of factors. Eigenvalues of 1 and Items loaded of at least 0.40, with no cross-loading of items above 0.40 were satisfy the criteria of construct validity (50).

The model was subsequently confirmed through partial confirmatory factor analysis (PCFA) using maximum likelihood analysis (MLA) with oblimin rotation. The incremental fit indices, namely the comparative fit index (CFI), normed fit index (NFI) and the Tucker Lewis index (TLI), were subsequently calculated. The absolute fit index, i.e., root mean square error of approximation (RMSEA), was also calculated and reported (51, 52).

2.4.3 Internal consistency and reliability analyses

Internal consistency and test–retest reliability were assessed using Cronbach’s alpha and intraclass correlation coefficients (ICCs), respectively. The criteria of accepting Cronbach’s alpha are equal to or above 0.70 (53). The criteria for interpretation of ICCs are based on Rosner, i.e. $ICC < 0.40$ is seen as poor agreement, $0.40 \leq ICC < 0.75$ is seen as fair to good agreement, and an $ICC \geq 0.75$ is excellent agreement (54).

The Item internal consistency (IIC) was measured by the Pearson correlation, which assess the relationship of each item to its hypothesized factor or domain. The IIC rule requires that the item should correlate $r \geq 0.4$ with its adjusted scale score (55). The test-retest reliability between two time-points was assessed after a gap of 6 weeks through Pearson’s correlation coefficient (ρ). A value of (ρ) more than 0.75 and p-value < 0.05 was considered as a significantly strong correlation (51, 52).

2.4.4 Known group validation

We hypothesized that participants with greater experience would be more able to identify falsified herbal supplement compared with their counterparts. Consequently for this study, participants were categorized into two groups based namely those with 1-10 years of experience and those with >10 years of experience. The known group validity was evaluated through one-way ANOVA test and a p-value less than 0.05 was considered acceptable.

2.5. Sample size calculation

The sample size calculation for the full study was based on the answers to the question “Do you know how to identify herbal supplements safety based on the product label?” in the pilot study.

According to the pilot study, the proportion of people who answered yes to this question was 44%. The alpha level was set at 5%, giving a 95% confidence interval. Precision (D) for the 95% confidence interval was fixed at 5% so that the 95% CI would have a maximum width of 10%. On the basis of these assumptions, a sample size n of 541 was required, assuming that nonresponse rates would be approximately 30%.

2.6 Sampling technique

To ensure representativeness, this study used a simple random sampling technique. In 2010, it was estimated that a total of 2000 community pharmacies are practicing across the UAE (47). The contact details and locations of community pharmacies in the areas chosen for study were taken from local business directories and the Yellow Pages.

After the sampling, the randomly selected pharmacies were stratified into groups or strata based on the community pharmacies’ locations. Accordingly, three strata were identified,

as follows: community pharmacies located in Abu Dubai, community pharmacies located in Dubai, and community pharmacies located in the Northern Emirates.

Once pharmacies had been selected up to a total of 541, Excel software was used to record all related data to serve as a sampling frame, reporting the name, type, location, email address, and phone number of each pharmacy. Each pharmacy was given an ID number, after which all the listed pharmacies were subjected to a simple random sample selection process. Community pharmacies selected for inclusion were subsequently categorized by type and location and subsequently visit.

2.7 Data collection

Selected community pharmacies across, Abu Dubai, Dubai and the Northern Emirates were visited between 27 January 2021 and 27 September 2021. The researchers explained the purpose of the research to the pharmacists and noted their email addresses. Face-to-face interviews were subsequently undertaken using the structured questionnaire, based on the pilot study, among those who agreed to participate.

2.8 Statistical analysis

Data analysis was performed using SPSS version 24. The participants answered the questionnaire where pertinent using a 5-point Likert scale (0 = “Never”, 1 = “Rarely”, 2 = “Sometimes”, 3 = “Often” and 4 = “Always”) (Supplementary file). Descriptive statistics, including frequencies and percentages for categorical variables and mean (SD) for continuous variables, were used to summarize the demographic and baseline characteristics of the study sample. To test the known group validity, the association between the falsified herbal supplements identification score (outcome variable) and year of experience (independent variables) was tested using one-way ANOVA. Statistical significance was considered at p-value less than 0.05.

2.9 Ethical consideration

The study was approved by the Institutional Ethical Review Committee of Ajman University. Before data collection, the purpose of the survey was explained to all potential community pharmacists. Community pharmacists were also informed that completion and submission of the questionnaire would be undertaken upon their consent. All participants signed the informed consent. No participant identities were recorded and confidentiality was guaranteed.




Figure 1: Flow chart for development and validation process.

3. Results

3.1 Demographic details of the participants

A total of 500 community pharmacists participated in the full study out of a possible total of 541 pharmacists and completed the questionnaire. Of the total participants, 328 (65.6%) were female and 172 (34.4%) were male. The average age of the participant community pharmacists was 32.2 ± 6.8 years.

Most of the participant community pharmacists were Arabic (Table 1) with a minority from the Emirati (14.0%), Asia (6.0%) and Africa (4.4%). Among the total number of community pharmacists taking part, 188 (37.6%) had between 1 to 10 years' experience and 312 (62.4%) have more than 10 years' experience (Table 1).

Table 1: Demographic information (n=500).

Demographics	Groups	Frequency	Percentage
Age (mean \pm S.D)	32.2 \pm 6.8		
Gender	Female	328	65.6
	Male	172	34.4
Age groups	18 to 24 years	396	79.2
	25 to 34 years	52	10.4
	\geq 35 years	52	10.4
Nationality	African	22	4.4
	Arabic	364	72.8
	Asian	30	6.0
	Emirati	70	14.0
	Western	14	2.8
Years of Experience	1-10 years	188	37.6
	More than 10 years	312	62.4

3.2 Validation analysis

3.2.1 Face/content validity

The first draft of the instrument comprised 31 items. After the draft was evaluated by the expert panel, ten of these items were modified based on their feedback. We subsequently determined that 7 items did not meet the minimum CVR of 0.78, and these were subsequently eliminated from the scale. The final 24-item scale had a CVI of 0.843.

3.2.2 Construct validity (factor analysis)

As mentioned, EFA using PCA with varimax rotation was used to assess the structure of the instrument's factors. The KMO measure of sampling adequacy was 0.891, and Bartlett's test of sphericity indicated significance (p -value < 0.001).

A five-factor solution was determined to have eigenvalues above 1 and accounted for 66.3% of the variance with factor 1 presenting 42.3% and factors 2, 3, 4 and 5 constituting 8.1%, 7.1%, 4.6% and 4.2% respectively. Items that factor loaded > 0.4 onto one component and demonstrated non-salient loading < 0.4 on another component were considered to be a single factor. A clear factor structure was thereby obtained (Table 2 & Figure 2).


Confirmation of the subsequent 5-factor model was achieved through PCFA using MLA with oblimin rotation. The KMO was 0.882, and Bartlett's test of sphericity demonstrated significance (p -value < 0.001). The distribution curve of the non-salient factor loading was normal with a mean value of 0.1. The null model χ^2 was 8239.25, and the χ^2 of the implied model was 945.57. The PCFA obtained values of 0.962 for NFI, 0.977 for CFI, and 0.987 for TLI; all values were greater than 0.95, and the RMSEA value was 0.03 (i.e., less than 0.06). Consequently, the model had a good fit.

Table 2: Content validity ratio and factor structure emerging from principle factor analysis.

	Item content	CVR	Component					Communalities
			1	2	3	4	5	
Factor 1	Restrictions on use by specific groups of consumers e.g. during pregnancy, during breastfeeding, for children under 3 years	0.83	0.776	0.208	0.128	0.019	0.264	0.731
Relevant identified uses of the substance or mixture and uses advised against	Relevant identified used, recommended use and restrictions on use	0.87	0.751	0.203	0.027	0.218	0.171	0.683
	Warning and cautions are clearly indicated on the product label	0.83	0.728	0.216	0.101	0.125	0.254	0.667
	Information on hazardous ingredients e.g. contains X - where X is a component that requires warning	0.81	0.675	0.229	0.336	0.226	0.035	0.673
	Information on the package insert match with the information on the product container	0.77	0.635	0.065	0.309	0.337	0.082	0.623
	Warning of Keep out of reach of children	0.74	0.618	0.099	0.198	0.180	0.382	0.643
	List of ingredients or reference to enclosed or attached information about list of ingredients	0.92	0.517	0.149	0.368	0.270	0.225	0.602
Factor 2	Dietary supplements container is safely sealed	0.79	0.161	0.782	0.008	0.093	0.339	0.762

Container/Closure and Hazards identification	Dietary supplements container and closure protect the product from the outside environment	0.83	0.099	0.731	0.116	-0.075	0.345	0.683
	The premises and shops selling the dietary supplements assure that the dietary supplements meet the proper specifications throughout their shelf life	0.81	0.327	0.686	0.259	0.062	0.107	0.659
	The container and the closure are appropriate for the dietary supplement product inside	0.86	0.196	0.684	0.300	0.125	0.139	0.631
	Information on the outer box of the dietary supplements match with the label on the container	0.74	0.125	0.645	0.310	0.295	-0.046	0.618
	All information on the dietary supplement labels are legible and indelible	0.93	0.353	0.486	0.375	0.254	-0.144	0.587
	The product labeled as Dietary supplements or food supplements	0.84	0.059	0.431	0.396	0.428	0.347	0.650
Factor 3	Trade name is spelt correctly	0.81	0.131	0.264	0.779	0.151	0.156	0.740
product authentic and identifier	The manufacturer's name and logo are Legible and correct	0.88	0.141	0.139	0.676	0.337	0.158	0.635
	The active ingredient name is spelt Correctly (scientific name/generic name)	0.92	0.335	0.235	0.664	0.058	0.052	0.614
	The dietary supplement product is registered in the country by the concerned Regulatory Authority	0.87	0.170	0.395	0.563	0.117	0.134	0.611
Factor 4	The size and Volume are clearly indicated in the product label	0.82	0.085	0.001	0.283	0.732	0.211	0.667
Packaging and product insert	The number of dosage units listed on the label matches with the number of dosage units stated on the container	0.78	0.346	0.107	0.063	0.716	0.003	0.719
	The dosage stated on the label is appropriate for the dietary supplement product in this form and strength	0.86	0.317	0.248	0.154	0.674	0.070	0.645
Factor 5	The manufacturing and expiry dates are clearly indicated on the label	0.84	0.237	0.315	-0.108	0.149	0.728	0.719
Handling and storage	The storage conditions are indicated on the label	0.93	0.341	0.140	0.316	0.049	0.685	0.707
	The product has been properly stored	0.96	0.265	0.188	0.294	0.129	0.655	0.638

Figure 2: Scree plot and component factors resulting from the PCA.



Internal consistency (Cronbach's alpha), IIC, and ICC were used to assess the reliability of the developed instrument. All factors demonstrated Cronbach's alpha coefficients above 0.70, with 0.940 for the full instrument. Meanwhile, all items met the IIC correlation standard of ≥ 0.40 . Finally, the instrument presented good ICC statistics of 0.940 (0.928 – 0.950) as well as statistical significance ($p < 0.001$).

The ICC for the factors ranged between 0.745 and 0.897. The reliability of factor 1 was reported at 0.897 with 95% confidence interval of (0.876 - 0.915). The factor 2 had an alpha value of 0.872, ICC = 0.846 - 0.895 for 95% CI. The factor 3 had an alpha value of 0.817, ICC = 0.778 – 0.851 for 95% CI. The factor 4 had an alpha value of 0.745, ICC = 0.778 – 0.844 for 95% CI. The factor 5 had an alpha value of 0.782, ICC = 0.731 – 0.825 for 95% CI. Further details are given in Table 3.

The instrument's test-retest reliability was measured through a correlation between the participants' identification scores for counterfeit and substandard herbal supplements at time points 1 and 2, with a 3-week gap; the correlation coefficient was 0.872 (p -value < 0.01)

Table 3. Reliability assessment criteria of the study scale (n=500).

Subscale	No. of items	Mean \pm SD	Cronbach's α	IIC	ICC (95% CI)
Factor 1	7	47.23 \pm 6.8	0.897	0.765 - 0.797	0.897 (0.876 - 0.915)
Factor 2	7	21.8 \pm 6.6	0.872	0.684 - 0.803	0.872 (0.846 - 0.895)
Factor 3	4	11.5 \pm 4.1	0.817	0.782 - 0.854	0.817 (0.778 - 0.851)

Factor 4	3	9.3 ± 3.1	0.745	0.778 – 0.844	0.745 (0.685 – 0.796)
Factor 5	3	10.5 ± 2.9	0.782	0.810 – 0.848	0.782 (0.731 – 0.825)
Total	24	76.5 ± 19.4	0.940	-----	0.940 (0.928 – 0.950)
Abbreviations: SD, (standard deviation); IIC, item-internal consistency; ICC, intraclass correlation (consistency ICC from 2-way mixed model).					

3.4 Known group validity

As shown in Table 4, the known group validity was assessed by one way ANOVA. A statistically significant relationship was seen between the experience in years and the reported falsified herbal supplement identification scores.

Those participants who had more than 10 years of experience more likely to identify falsified herbal supplements compared to those who had only 1 to 10 years of experience ($p < 0.001$).

Table 4. Substandard and falsified herbal supplements identification scores by experience years.

Experience years	herbal supplements safety identification scores			
	Mean	± SD	95% confidence interval	
			Lower limit	Upper limit
1-10 years	79.8	23.6	75.08	86.66
More than 10 years	83.7	22.1	80.12	87.41

4. Discussion

We believe this is one of the first published studies to develop a method (an instrument) that can help community pharmacists identify falsified and substandard herbal supplements within their pharmacies. This is important given the anticipated growth in sales of herbal supplements driven by a likely increase in the number of patients seeking herbal supplements from community pharmacies in the future, exacerbated by the current COVID-19 pandemic with patients seeking herbal medicines in the absence of proven effective pharmaceuticals assisted by studies demonstrating their benefits (1, 3, 56-60). In addition, growing reports of falsified or adulterated herbal supplements, with concerns for the health of patients (13, 21, 22, 28).

Encouragingly, the content validity index yielded a satisfactory value of 0.843, with the Cronbach's alpha seen as good (0.940), with the alpha values for the five components of the scale also seen as very acceptable (0.745 to 0.897). The instrument's temporal stability was also seen as good as evidenced by the results of test-retest examinations.

Five different components of the conceptual model were identified as having eigenvalues larger than one, as predicted by the model, which is also encouraging. This accounted for 66.3 percent of the variation. The correlation matrix was factorable, as evidenced by the KMO value of 0.891 and the statistical significance of Bartlett's test of sphericity ($p < 0.001$). The PCFA analysis verified the 5-factor model solution and showed a strong match; consequently, this measurement scale was seen as robust in identifying key areas including the manufacturer's name and logo, the name of active ingredients, and if the herbal supplement product was registered with the relevant Regulatory Authority as well as double-check critical package and product insert information. Encouragingly as well, the instrument could distinguish across groups with varying experience levels, which is to be expected.

The length of the instrument and the time it took to complete the questionnaire were viewed as positive points, which resulted in a high response rate and excellent levels of respondent accuracy.

Consequently, we believe this tool can help advance the role of community pharmacists in the appropriate and safe dispensing of herbal supplements, building on the comments of Harnett et al (2019) (37). Future studies can research the use of the tool in community pharmacies to assess whether falsified or adulterated herbal supplements can readily be detected whilst relying on surveillance using for instance DNA barcodes or AMB techniques to detect contaminated or falsified products (27-29, 46).

Such studies can also help to develop a more complete map of the routes via which fake herbal supplements are trafficked including concerns with free trade zones and their implications (61), as well as a better understanding of their effects on consumers, the industry, and key state-level groups. Furthermore, our tool should help community pharmacists address one of their key ethical responsibilities, that is being vigilant of any harm associated with herbal supplements and subsequently intervening in the case of any perceived significant risk of harm related to the dispensing of herbal supplements(11, 39). Alongside this, the mass sale of counterfeit products via internet shopping channels also needs to be addressed. However, this is outside the scope of the current project.

Overall, we believe we have developed a robust and valid tool building on the Lome and other initiatives for falsified medicines (44). This is because of the many stages employed in its development. Consequently, we are confident in using the questionnaire in future studies to assess the extent of fraudulent herbal supplements in UAE and across countries in the future. The findings should enhance the role of the community pharmacists in treating suitable patients with herbal supplements, and being confident in the product they dispense recognising their legal requirements. This will be important for future patient safety and sales. We will also now work with Governments and Pharmacy Groups in UAE and wider to see how we can assist with identifying falsified herbal supplements in the future based on our study findings.

We are aware of a number of limitations with our study. Firstly, we conducted this study in only one country. Secondly, we have not tested the tool we have developed in practice.

However, we believe that in view of our robust methodology we would expect the tool to work in practice and across countries since these problems are not confined to community pharmacists in UAE.

4. Conclusions

In conclusion, this study developed and validated a new scale for safe dispensing of the herbal supplement formulations. The final instrument appeared concise and easy to administer, making it appropriate for use in community pharmacies. Ultimately, this tool can facilitate collaboration between community pharmacist, health regulatory authorities and inspection authorities to identify falsified supplements. As a result, this study could provide decision-makers in the public and private sectors with informed insights into the worldwide counterfeit herbal supplement trade. This will enable them to create policy solutions that are both relevant and effective in the future.

List of abbreviations

AU: Ajman University

UAE: United Arab Emirates

IIC: item internal consistency

ICCs: intraclass correlation coefficients

CVR: content validity ratio

CVI: content validity Index

EFA: Exploratory factor analysis

PCA: principal component analysis

KMO: Kaiser-Mayer-Olkin

PCFA: partial confirmatory factor analysis

TLI: Tucker-Lewis index

NFI: normed fit index

CFI: comparative fit index

RMSEA: root mean square error of approximation

References

1. Market Data Forecast. Herbal Medicine Market. April 2021. Available at URL: <https://www.marketdataforecast.com/market-reports/herbal-medicine-market>.
2. Byard RW, Musgrave I, Maker G, Bunce M. What risks do herbal products pose to the Australian community? *Med J Aust.* 2017;206(2):86-90.
3. Alsayari A, Almghaslah D, Khaled A, Annadurai S, Alkhairy MA, Alqahtani HA, et al. Community Pharmacists' Knowledge, Attitudes, and Practice of Herbal Medicines in Asir Region, Kingdom of Saudi Arabia. *Evidence-Based Complementary and Alternative Medicine.* 2018;2018:1568139.
4. Eddouks M, Andrade-Cetto A, Heinrich M, De Feo V, Cho WC. Editorial: Mechanisms of Traditional Medicinal Plants Used to Control Type 2 Diabetes or Metabolic Syndrome. *Frontiers in Pharmacology.* 2021;11.
5. Geck MS, Cristians S, Berger-González M, Casu L, Heinrich M, Leonti M. Traditional Herbal Medicine in Mesoamerica: Toward Its Evidence Base for Improving Universal Health Coverage. *Frontiers in Pharmacology.* 2020;11.
6. Bhat BB, Udupa N, Sreedhar D. Herbal Products Regulations in a Few Countries-A Brief Overview. *Current drug discovery technologies.* 2019;16(4):368-71.
7. Ekar T, Kreft S. Common risks of adulterated and mislabeled herbal preparations. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.* 2019;123:288-97.
8. Nuryunarsih D. Counterfeit Herbal Medicine adulterated with chemical drugs in Indonesia: NADFC Public warning 2011-2014. *International Journal of Herbs, Spices and Medicinal Plants.* 2016;1 (1):2 - 17.

9. Holleran G, Scaldaferrri F, Gasbarrini A, Currò D. Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials. *Phytother Res.* 2020;34(1):77-93.
10. Calitz C, du Plessis L, Gouws C, Steyn D, Steenekamp J, Muller C, et al. Herbal hepatotoxicity: current status, examples, and challenges. *Expert opinion on drug metabolism & toxicology.* 2015;11(10):1551-65.
11. Popattia AS, Hattingh L, La Caze A. Improving pharmacy practice in relation to complementary medicines: a qualitative study evaluating the acceptability and feasibility of a new ethical framework in Australia. *BMC Med Ethics.* 2021;22(1):3.
12. Brown AC. Kidney toxicity related to herbs and dietary supplements: Online table of case reports. Part 3 of 5 series. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.* 2017;107(Pt A):502-19.
13. Kum KY, Kirchhof R, Luick R, Heinrich M. Danshen (*Salvia miltiorrhiza*) on the Global Market: What Are the Implications for Products' Quality? *Frontiers in Pharmacology.* 2021;12.
14. Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A, et al. Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. *British journal of clinical pharmacology.* 2015;79(4):578-92.
15. Dwyer JT, Coates PM, Smith MJ. Dietary Supplements: Regulatory Challenges and Research Resources. *Nutrients.* 2018;10(1):41.
16. Mayo Clinic. Healthy Lifestyle Nutrition and healthy eating - Herbal supplements: What to know before you buy 2021. Available at URL: <https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/herbal-supplements/art-20046714>.
17. Xiong Y, Gao M, van Duijn B, Choi H, van Horsen F, Wang M. International policies and challenges on the legalization of traditional medicine/herbal medicines in the fight against COVID-19. *Pharmacological research.* 2021;166:105472.
18. Khan SU, Khan MU, Riaz H, Valavoor S, Zhao D, Vaughan L, et al. Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map. *Annals of internal medicine.* 2019;171(3):190-8.
19. Parks NE, Jackson-Tarleton CS, Vacchi L, Merdad R, Johnston BC. Dietary interventions for multiple sclerosis-related outcomes. *The Cochrane database of systematic reviews.* 2020;5(5):Cd004192.
20. Jairoun AA, Al-Hemyari SS, El-Dahiyat F, Hassali MA, Shahwan M, Al Ani MR, et al. Suboptimal Health, Dietary Supplementation, and Public Health Approaches to Regulatory Challenges in Dubai. *Journal of primary care & community health.* 2020;11:2150132720911303.
21. Newsmax. Fake Herbal Supplements Found at Walmart, Target, Walgreens. 2015 Available at URL: <https://www.newsmax.com/TheWire/fake-herbal-supplements-walmart/2015/02/03/id/622342/>
22. BottomLineInc. Are Your Herbal Supplements Contaminated or Fake? 2014 Available at URL: <https://bottomlineinc.com/health/herbs/are-your-herbal-supplements-contaminated-or-fake>
23. Ozdemir B, Sahin I, Kapucu H, Celbis O, Karakoc Y, Erdogan S, et al. How safe is the use of herbal weight-loss products sold over the internet? *Human & experimental toxicology.* 2013;32(1):101-6.
24. Wiest J, Schollmayer C, Gresser G, Holzgrabe U. Identification and quantitation of the ingredients in a counterfeit Vietnamese herbal medicine against rheumatic diseases. *Journal of pharmaceutical and biomedical analysis.* 2014;97:24-8.
25. Khan MA, Badshah A, Shahid M. PHARMACEUTICAL EVALUATION AND TOXICOLOGICAL QUANTIFICATION OF HEAVY METALS AND ADULTERATED ALLOPATHIC CONTENTS IN RAW AND

- FINISHED DOSAGE FORM OF ANTIHYPERTENSIVE HERBAL PRODUCTS. African journal of traditional, complementary, and alternative medicines : AJTCAM. 2016;13(6):54-60.
26. Frommenwiler DA, Reich E, Sudberg S, Sharaf MH, Bzhelyansky A, Lucas B. St. John's Wort versus Counterfeit St. John's Wort: An HPTLC Study. Journal of AOAC International. 2016;99(5):1204-12.
 27. Little DP. Authentication of Ginkgo biloba herbal dietary supplements using DNA barcoding. Genome. 2014;57(9):513-6.
 28. Raclariu AC, Paltinean R, Vlase L, Labarre A, Manzanilla V, Ichim MC, et al. Comparative authentication of Hypericum perforatum herbal products using DNA metabarcoding, TLC and HPLC-MS. Sci Rep. 2017;7(1):1291.
 29. Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Medicine. 2013;11(1):222.
 30. Marković-Peković V, Grubiša N, Burger J, Bojanić L, Godman B. Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications. J Res Pharm Pract. 2017;6(2):120-5.
 31. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. Research in social & administrative pharmacy. 2021;17(1):2032-5.
 32. Hedima EW, Adeyemi MS, Ikunaiye NY. Community Pharmacists: On the frontline of health service against COVID-19 in LMICs. Res Social Adm Pharm. 2021;17(1):1964-6.
 33. Alkharfy KM. Community pharmacists' knowledge, attitudes and practices towards herbal remedies in Riyadh, Saudi Arabia. East Mediterr Health J. 2010;16(9):988-93.
 34. Asmelashe Gelayee D, Binega Mekonnen G, Asrade Atnafe S, Birarra MK, Asrie AB. Herbal Medicines: Personal Use, Knowledge, Attitude, Dispensing Practice, and the Barriers among Community Pharmacists in Gondar, Northwest Ethiopia. Evidence-based complementary and alternative medicine : eCAM. 2017;2017:6480142.
 35. Shraim NY, Shawahna R, Sorady MA, Aiesh BM, Alashqar GS, Jitan RI, et al. Community pharmacists' knowledge, practices and beliefs about complementary and alternative medicine in Palestine: a cross-sectional study. BMC Complementary and Alternative Medicine. 2017;17(1):429.
 36. Ung COL, Harnett JE, Hu H, Desselle SP. Barriers to pharmacists adopting professional responsibilities that support the appropriate and safe use of dietary supplements in the United States: Perspectives of key stakeholders. Am J Health Syst Pharm. 2019;76(13):980-90.
 37. Harnett JE, Ung COL, Hu H, Sultani M, Desselle SP. Advancing the pharmacist's role in promoting the appropriate and safe use of dietary supplements. Complement Ther Med. 2019;44:174-81.
 38. Salman Popattia A, Winch S, La Caze A. Ethical responsibilities of pharmacists when selling complementary medicines: a systematic review. Int J Pharm Pract. 2018;26(2):93-103.
 39. Salman Popattia A, La Caze A. An ethical framework for the responsibilities of pharmacists when selling complementary medicines. Res Social Adm Pharm. 2021;17(5):850-7.
 40. The Guardian. Differences between EU and US nutrition labels go far beyond ounces and grams. 2015. Available at URL: <https://www.theguardian.com/lifeandstyle/2015/sep/08/food-labeling-us-fda-eu-health-food-safety>
 41. European Commission. Food: EU consumers to benefit from better labelling as of 13 December 2014. Available at URL: https://ec.europa.eu/commission/presscorner/detail/en/IP_14_2560

42. FDA. Dietary Supplement Labeling Guide: Chapter I. General Dietary Supplement Labeling. 2005. Available at URL: <https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide-chapter-i-general-dietary-supplement-labeling#1-2>
43. Government of Dubai. Apply for Consumer Products Registration (MONTAJI). 2022.: Available at URL: <https://hub.dm.gov.ae/link/servicedetails?servicecode=3560> [
44. WHO. Launch of the Lomé Initiative. 2020. Available at URL: <https://www.who.int/dg/speeches/detail/launch-of-the-lom%C3%A9-initiative>.
45. Ogunleye OO, Basu D, Mueller D, Sneddon J, Seaton RA, Yinka-Ogunleye AF, et al. Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. *Frontiers in pharmacology*. 2020;11(1205).
46. Wallace LJ, Boilard SMAL, Eagle SHC, Spall JL, Shokralla S, Hajibabaei M. DNA barcodes for everyday life: Routine authentication of Natural Health Products. *Food Research International*. 2012;49(1):446-52.
47. Jairoun AA, Al-Hemyari SS, Shahwan M, El-Dahiyat F, Jamshed S. Scale validation for the identification of falsified hand sanitizer: public and regulatory authorities perspectives from United Arab Emirates. *BMC Public Health*. 2020;20(1):1595.
48. Rungtusanatham M. Let's Not Overlook Content Validity. *Decision Line*. July 1998:10 - 3.
49. Lawshe C. A quantitative approach to content validity. *Pers Psychol*. 1975;28:563–75.
50. Straub D BM-C, Gefen D. Validation guidelines for IS positivist research. *Communications of the Association for Information Systems*. 2004;13:380-427.
51. Cohen J. *Statistical power analysis for the behavioral sciences*. 1988. Second Edition. LAWRENCE ERLBAUM ASSOCIATES, PUBLISHERS. Available at URL: <http://utstat.toronto.edu/~brunner/oldclass/378f16/readings/CohenPower.pdf>
52. Devellis RF, editor *Scale Development: Theory and Applications* 1991.
53. Nunnally J. *Psychometric Theory: Second Edition*. McGraw-Hill, New York.; 1978.
54. Rosner B. *Fundamentals of biostatistics, Fifth Edition*: Pacific Grove, CA : Duxbury; 2000.
55. Ware JE, Jr., Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. *International Quality of Life Assessment. J Clin Epidemiol*. 1998;51(11):945-52.
56. Sefah I, Ogunleye O, Essah D, Oponga S, Rizvi N, Wamaitha A, et al. Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications. *Frontiers in pharmacology*. 2021;11(2055).
57. Khanna K, Kohli SK, Kaur R, Bhardwaj A, Bhardwaj V, Ohri P, et al. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle. *Phytomedicine*. 2021;85:153361.
58. Feng Z, Yang J, Xu M, Lin R, Yang H, Lai L, et al. Dietary supplements and herbal medicine for COVID-19: A systematic review of randomized control trials. *Clin Nutr ESPEN*. 2021;44:50-60.
59. Silveira D, Prieto-Garcia JM, Boylan F, Estrada O, Fonseca-Bazzo YM, Jamal CM, et al. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? *Frontiers in Pharmacology*. 2020;11.
60. Brendler T, Al-Harrasi A, Bauer R, Gafner S, Hardy ML, Heinrich M, et al. Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. *Phytother Res*. 2021;35(6):3013-31.
61. OECD, Office EUIP. *Trade in Counterfeit Goods and Free Trade Zones*: Available at URL: <https://www.oecd.org/gov/trade-in-counterfeit-goods-and-free-trade-zones-9789264289550-en.htm>; 2018 [Available from: <https://www.oecd-ilibrary.org/content/publication/9789264289550-en>.

Appendix

Visual assessment of herbal supplements products

This tool is designed to help community pharmacist and other health professionals carry out a visual assessment of herbal supplements for signs of unsafe, unregulated or falsified dietary herbal supplements product such as improper packaging, labelling or description of dosage.

[How frequently you do check or evaluate the following information on herbal supplement' label when you dispense herbal supplement product?].

How frequently you check the following information	
	Response
Relevant identified uses of the substance or mixture and uses advised against	
1. Restrictions on use by specific groups of consumers e.g. during pregnancy, during breastfeeding, for children under 3 years	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
2. Relevant identified used, recommended use and restrictions on use	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
3. Warning and cautions are clearly indicated on the product label	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
4. Information on hazardous ingredients e.g. contains X - where X is a component that requires warning	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
5. Information on the package insert match with the information on the product container	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
6. Warning of Keep out of reach of children	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
7. List of ingredients or reference to enclosed or attached information about list of ingredients	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
Container/Closure and Hazards identification	
8. Herbal supplements container is safely sealed	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
9. Herbal supplements container and closure protect the product from the outside environment	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
10. The premises and shops selling the Herbal supplements assure that the Herbal supplements meet the proper specifications throughout its Shelf life	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
11. The container and the closure are appropriate for the Herbal supplements product inside	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
12. information on the outer box of Herbal supplements match with the label on the container	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
13. All information on the Herbal supplements label are legible and indelible	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
14. The product labeled as Herbal supplements or food supplements	Never <input type="checkbox"/> Rarely <input type="checkbox"/> Sometimes <input type="checkbox"/> often <input type="checkbox"/> Always <input type="checkbox"/>
Herbal supplement authentic and identifier	

15. Trade name is spelt correctly	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
16. The manufacturer's name and logo are Legible and correct	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
17. The active ingredient name is spelt Correctly (scientific name/generic name)	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
18. Herbal supplements product is registered in the country by the concerned Regulatory Authority	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
Packaging and product insert					
19. The size and Volume are clearly indicated in the product label	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
20. The number of dosage units listed on the label matches with the number of dosage units stated on the container	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
21. The dosage stated on the label is appropriate for the Herbal supplements product in this form and strength	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
Handling and storage					
22. The manufacturing and expiry dates are clearly indicated on the label	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
23. The storage conditions are indicated on the label	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always
24. The product has been properly stored	Never	<input type="checkbox"/> Rarely	<input type="checkbox"/> Sometimes	<input type="checkbox"/> often	<input type="checkbox"/> Always